PYC Therapeutics (ASX:PYC) says that one of its candidates for a blinding eye disease of childhood called Autosomal Dominant Optic Atrophy (ADOA) has demonstrated disease-modifying potential in ‘retina in a dish’ models.
PYC Therapeutics is developing precision therapies for patients with genetic diseases and no treatment options.
The company said the ADOA candidate
has now also demonstrated a suitable safety profile for progression into human trials following the completion of Good Laboratory Practice (GLP) toxicology studies in Non-Human Primates (NHPs).
It said the results of the GLP toxicology studies demonstrate that PYC-001 was safe and well-tolerated at all doses tested with a No Observable Adverse Event Limit (NOAEL) of 30 micrograms per eye – the highest dose of PYC-001 evaluated in these studies. PYC said it now has all the information required to submit a regulatory application to progress into human trials for PYC-001.
